Genmab AS

Genmab AS EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genmab AS (GMAB) as of Nov 22, 2026 is 1.25 B USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 6.70 B USD — a change of -81.34% (lower).

EBITDA

1.25 BUSD

YoY

-81.34%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genmab AS is 2025 1.25 B USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genmab AS was 2024 6.70 B USD. It decreases by -81.34% lower compared to the previous year.

The Genmab AS EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
1.38 B USD
Jan 1, 2019
2.64 B USD
Jan 1, 2020
6.31 B USD
Jan 1, 2021
2.95 B USD
Jan 1, 2022
6.27 B USD
Jan 1, 2023
5.32 B USD
Jan 1, 2024
6.70 B USD
Jan 1, 2025
1.25 B USD
The Genmab AS EBITDA history
YEAREBITDAYoY
1.25 BUSD-81.34%
6.70 BUSD+25.97%
5.32 BUSD-15.09%
6.27 BUSD+112.22%
2.95 BUSD-53.22%
6.31 BUSD+139.31%
2.64 BUSD+91.12%
1.38 BUSD+2.69%
1.34 BUSD+27.67%
1.05 BUSD+44.15%
730.38 MUSD+175.43%
265.18 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genmab AS is 1.25 B USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genmab AS changed from 6.70 B USD to 1.25 B USD, representing a -81.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Genmab AS since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Genmab AS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Genmab AS

All Key Metrics — Genmab AS